Načítá se...
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients
Sorafenib is an orally administered multikinase inhibitor that exhibits antiangiogenic and antitumor activity. Few investigators have been able to correlate cumulative sorafenib dose or total exposure to pharmacodynamic effects. This discrepancy may be in part due to poorly understood protein bindin...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3652000/ https://ncbi.nlm.nih.gov/pubmed/22089297 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9767-5 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|